免疫检查点抑制剂与抗血管生成剂的联合应用是癌症治疗中一种有前途的新方法。免疫检查点抑制剂阻断了帮助癌细胞逃避免疫系统的信号，而抗血管生成剂则靶向供应肿瘤营养和氧气的血管，限制其生长。重要的是，这种联合应用基于分子和细胞机制引发协同效应，使反应率和无进展生存期较单一治疗更好。然而，这些组合也可能导致副作用增加，需要密切监测。© 2023. Springer Nature Limited 独家许可。

The combination of immune checkpoint inhibitors and anti-angiogenic agents is a promising new approach in cancer treatment. Immune checkpoint inhibitors block the signals that help cancer cells evade the immune system, while anti-angiogenic agents target the blood vessels that supply the tumour with nutrients and oxygen, limiting its growth. Importantly, this combination triggers synergistic effects based on molecular and cellular mechanisms, leading to better response rates and longer progression-free survival than treatment alone. However, these combinations can also lead to increased side effects and require close monitoring.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.